.Pharmacolibrary.Drugs.ATC.N.N03AF03

Information

Rufinamide is an antiepileptic drug primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in both children and adults. It is an approved medication used for epilepsy today.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after oral administration.

References

1. Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590

2. Perucca, E, et al., & Fuseau, E (2008). Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49(7) 1123–1141. DOI:10.1111/j.1528-1167.2008.01665.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18503564

3. Xu, M, et al., & Li, W (2016). Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects. European journal of drug metabolism and pharmacokinetics 41(5) 541–548. DOI:10.1007/s13318-015-0291-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26294172

Revisions

• 06/2025 initial generated model